Bemarituzumab (FUT8-KO)

Bemarituzumab (FUT8-KO) is an anti-FGFR2b monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Bemarituzumab (FUT8-KO) lacks a core fucose in the polysaccharide portion of the Fc domain of the antibody, and results in a high affinity to human FcγRIIIa[1].

Product Specifications

UNSPSC

12352203

Target

FGFR; Interleukin Related

Type

Reference compound

Related Pathways

Immunology/Inflammation; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/bemarituzumab-fut8-ko.html

Purity

99.74

Smiles

[Bemarituzumab(FUT8-KO)]

Molecular Weight

(143.86 kDa)

References & Citations

[1]Xiang H, et al., Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer. MAbs. 2021 Jan-Dec;13 (1) :1981202.